ABK Biomedical
@abkbiomedical.bsky.social
Sharing the observations made by Dr. William Rilling and the Route90 study team at Medical College of Wisconsin. Great Eye90 microspheres insight!
Read more: cancer.mcw.edu/stories/rout...
Read more: cancer.mcw.edu/stories/rout...
ROUTE 90 Trial Brings Cutting-Edge Radiation Therapy to Patients with Liver Cancer | Medical College of Wisconsin Cancer Center
A multi-center trial is testing a next-generation therapy that delivers targeted radiation directly to tumors with greater precision and visibility than ever before.
cancer.mcw.edu
December 19, 2025 at 10:44 PM
Sharing the observations made by Dr. William Rilling and the Route90 study team at Medical College of Wisconsin. Great Eye90 microspheres insight!
Read more: cancer.mcw.edu/stories/rout...
Read more: cancer.mcw.edu/stories/rout...
ABK is proud to share that the first Canadian patient has been successfully treated with Eye90 microspheres® as part of the Route90 clinical trial.
A sincere thank you to Dr. Rajvot Dhatt, his outstanding team at Vancouver General Hospital, and all other contributors supporting this study.
A sincere thank you to Dr. Rajvot Dhatt, his outstanding team at Vancouver General Hospital, and all other contributors supporting this study.
November 21, 2025 at 11:46 PM
ABK is proud to share that the first Canadian patient has been successfully treated with Eye90 microspheres® as part of the Route90 clinical trial.
A sincere thank you to Dr. Rajvot Dhatt, his outstanding team at Vancouver General Hospital, and all other contributors supporting this study.
A sincere thank you to Dr. Rajvot Dhatt, his outstanding team at Vancouver General Hospital, and all other contributors supporting this study.
Did you know it’s Interventional Oncology (IO) Awareness Week?
ABK Biomedical is proud to support & contribute to the growing field of IO with an innovative approach to radioembolization with Eye90 microspheres® and our Route90 clinical trial.
www.ioawareness.org
#IOAwarenessWeek #Y90 #IKnowIO
ABK Biomedical is proud to support & contribute to the growing field of IO with an innovative approach to radioembolization with Eye90 microspheres® and our Route90 clinical trial.
www.ioawareness.org
#IOAwarenessWeek #Y90 #IKnowIO
October 29, 2025 at 1:40 AM
Did you know it’s Interventional Oncology (IO) Awareness Week?
ABK Biomedical is proud to support & contribute to the growing field of IO with an innovative approach to radioembolization with Eye90 microspheres® and our Route90 clinical trial.
www.ioawareness.org
#IOAwarenessWeek #Y90 #IKnowIO
ABK Biomedical is proud to support & contribute to the growing field of IO with an innovative approach to radioembolization with Eye90 microspheres® and our Route90 clinical trial.
www.ioawareness.org
#IOAwarenessWeek #Y90 #IKnowIO
ABK Biomedical Raises US$35M in Series D Financing
Grateful for J.P. Morgan Life Sciences Private Capital leading this round, along with our outstanding syndicate of existing investors!
www.prnewswire.com/news-release...
Grateful for J.P. Morgan Life Sciences Private Capital leading this round, along with our outstanding syndicate of existing investors!
www.prnewswire.com/news-release...
ABK Biomedical Raises US$35M in Series D Financing
/PRNewswire/ - ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable...
www.prnewswire.com
October 14, 2025 at 1:58 PM
ABK Biomedical Raises US$35M in Series D Financing
Grateful for J.P. Morgan Life Sciences Private Capital leading this round, along with our outstanding syndicate of existing investors!
www.prnewswire.com/news-release...
Grateful for J.P. Morgan Life Sciences Private Capital leading this round, along with our outstanding syndicate of existing investors!
www.prnewswire.com/news-release...
The latest article on Y-90 in Radiation Oncology highlights the increasing body of evidence supporting its use in treating patients w/liver cancer. ABK’s anticipated Route90 study results should contribute valuable L1 data to this expanding evidence base. ro-journal.biomedcentral.com/articles/10....
Research trends of selective internal radiation therapy for liver cancer: a bibliometric analysis - Radiation Oncology
Background Liver cancer is a major contributor to cancer-related mortality. Selective internal radiation therapy (SIRT) for liver cancer has garnered increasing attention. This study aims to comprehen...
ro-journal.biomedcentral.com
September 18, 2025 at 4:01 PM
The latest article on Y-90 in Radiation Oncology highlights the increasing body of evidence supporting its use in treating patients w/liver cancer. ABK’s anticipated Route90 study results should contribute valuable L1 data to this expanding evidence base. ro-journal.biomedcentral.com/articles/10....
As published in a recent JVIR article, Y90 post-procedure PET/SPECT imaging is shown to inform better patient follow-up. Looking forward to seeing how Eye90 microspheres Precision Dosimetry® compares to Y90 PET/SPECT when ABK’s Route90 clinical trial reads out. www.jvir.org/article/S105...
Prediction of Recurrence of Hepatocellular Carcinoma Following Radiation Segmentectomy with Resin Microspheres Based on Underdosed Tumor Volume on Yttrium-90 Positron Emission Tomography/CT Dosimetry
To evaluate the use of immediate post–yttrium-90 (90Y)-radiation segmentectomy (RS)
positron emission tomography (PET)/computed tomography (CT) and dosimetry software
in predicting incomplete response...
www.jvir.org
September 8, 2025 at 3:09 AM
As published in a recent JVIR article, Y90 post-procedure PET/SPECT imaging is shown to inform better patient follow-up. Looking forward to seeing how Eye90 microspheres Precision Dosimetry® compares to Y90 PET/SPECT when ABK’s Route90 clinical trial reads out. www.jvir.org/article/S105...
ABK’s timely development of breakthrough Eye90 microsphere technology -- aimed at helping a rapidly growing global liver cancer population: www.nytimes.com/2025/07/28/w...
3 Out of 5 Liver Cancer Cases Are Preventable, Study Finds
www.nytimes.com
September 4, 2025 at 12:44 AM
ABK’s timely development of breakthrough Eye90 microsphere technology -- aimed at helping a rapidly growing global liver cancer population: www.nytimes.com/2025/07/28/w...
Review the 6-month interim results from our interim safety, effectiveness, and multimodal imageability of imageable glass microsphere yttrium-90 (90Y) radioembolization for unresectable HCC in a first-in-human trial. www.jvir.org/article/S105...
Imageable Radioembolization Microspheres for Treatment of Unresectable Hepatocellular Carcinoma: Interim Results from a First-in-Human Trial
To determine 6-month interim safety, effectiveness, and multimodal imageability of
imageable glass microsphere yttrium-90 (90Y) radioembolization for unresectable hepatocellular
carcinoma (HCC) in a f...
www.jvir.org
May 29, 2025 at 4:46 PM
Review the 6-month interim results from our interim safety, effectiveness, and multimodal imageability of imageable glass microsphere yttrium-90 (90Y) radioembolization for unresectable HCC in a first-in-human trial. www.jvir.org/article/S105...
ABK Biomedical is now on BlueSky! Come chat with us and learn more about how EYE90 fits into the treatment of HCC. #interventionaloncology #precisionmedicine #Y90 #cancertherapies www.abkbiomedical.com
May 29, 2025 at 4:06 PM
ABK Biomedical is now on BlueSky! Come chat with us and learn more about how EYE90 fits into the treatment of HCC. #interventionaloncology #precisionmedicine #Y90 #cancertherapies www.abkbiomedical.com